Issue brief |
01 September 2021

Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies


This brief outlines actionable steps the U.S. government can take to hold Cepheid accountable for transparent, fair, and equitable pricing of GeneXpert tests and ensure public return on public investment for health technologies developed using U.S. government funding.

Continue Reading